EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Acyclovir‐Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series

Jenna Nunn iD, Ahmed Ahmed iD, Srividhya Senthil iD, Oana Mirci-Danicar, Denise Bonney, Claire Horgan iD, Omima Mustafa, Robert Wynn, Malcolm Guiver, Ramya Nataraj

Transplant Infectious Disease · 2026-03 · 28 (2)

DOI: 10.1111/tid.70162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, online erschienen am 13.01.2026. Verfasst von Jenna Nunn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Haematology and Bone Marrow Transplant, Manchester University Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Antiviral Agents, Acyclovir, Drug Resistance, Viral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Herpes simplex virus (HSV) infection is a significant risk in hematopoietic stem cell transplant (HSCT) recipients, and antiviral resistance poses many clinical challenges.

Methods

A retrospective case series of eight pediatric patients with acyclovir‐resistant HSV infection, determined via genotypic sequencing, post allogeneic HSCT between 2012 and 2025.

Results

Indications for HSCT included primary immunodeficiency, sickle cell disease, myelodysplastic syndrome (MDS), and relapsed/refractory leukemia. All patients received acyclovir prophylaxis. TK mutations were most common ( n = 7, 87.5%). Infections manifested as mucocutaneous disease, pneumonitis, keratitis, enterocolitis, and blood viremia. A total of 87.5% of patients ( n = 7) were treated with second‐line antivirals (foscarnet and/or cidofovir), and three patients were treated with third‐line antivirals (pritelivir). Treatment was complicated by nephrotoxicity ( n = 3, 37.5%). Adjunct treatments included intravenous immunoglobulin ( n = 3, 37.5%) and donor lymphocyte infusion ( n = 1, 12.5%). Poor outcomes were seen across the cohort, including death ( n = 3, 37.5%). T‐cell depletion was used in 50% of patients ( n = 4). Concomitant immunosuppressive therapy was used in 100% of patients ( n = 8) and high‐dose steroids were used in 50% of patients ( n = 4). Graft versus host disease occurred in four patients (50%). Secondary complications included transplant‐associated thrombotic microangiopathy ( n = 3, 37.5%), idiopathic pulmonary syndrome ( n = 3, 37.5%), and graft failure ( n = 1, 12.5%).

Conclusion

Acyclovir‐resistant HSV infection in pediatric HSCT recipients is associated with high morbidity and mortality, limited therapeutic options, and significant treatment‐related nephrotoxicity. Early recognition, early resistance testing, prompt initiation of second‐line therapy, and weaning of immunosuppression are critical. Emerging therapies, such as helicase‐primase inhibitors and adoptive T‐cell therapy, hold promise but remain limited by access and pediatric data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationAntiviral AgentsAcyclovirDrug Resistance, ViralHerpes SimplexSimplexvirusHumansChildFemaleMaleRetrospective StudiesChild, PreschoolAdolescentTransplantation, HomologousInfant

Stichwörter der Autor:innen

HSV infectionshematopoietic stem cell transplantationrefractory/resistant HSVrisk factors

Substanzen

Antiviral AgentsAcyclovir

Autor:innen und Institutionen

  • Department of Paediatric Haematology and Bone Marrow Transplant, Manchester University Foundation Trust, Manchester, UK.
  • Department of Virology, Manchester University Foundation Trust, Manchester, UK.

ORCID-Profile: Jenna Nunn, Ahmed Ahmed, Srividhya Senthil, Claire Horgan

Zitieren

APA

Nunn, J., Ahmed, A., Senthil, S., Mirci-Danicar, O., Bonney, D., Horgan, C., Mustafa, O., Wynn, R., Guiver, M., & Nataraj, R. (2026). Acyclovir‐Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series. Transplant Infectious Disease, 28(2). https://doi.org/10.1111/tid.70162

Vancouver

Nunn J, Ahmed A, Senthil S, Mirci-Danicar O, Bonney D, Horgan C, et al. Acyclovir‐Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series. Transplant Infectious Disease. 2026;28(2). doi:10.1111/tid.70162

BibTeX
@article{Nunn2026,
  author = {Nunn, Jenna and Ahmed, Ahmed and Senthil, Srividhya and Mirci-Danicar, Oana and Bonney, Denise and Horgan, Claire and Mustafa, Omima and Wynn, Robert and Guiver, Malcolm and Nataraj, Ramya},
  title = {Acyclovir‐Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series},
  journal = {Transplant Infectious Disease},
  year = {2026},
  volume = {28},
  number = {2},
  doi = {10.1111/tid.70162}
}
Kostenlos starten →